Regenerative Patch Technologies' CPCB-RPE1 successfully implanted in AMD patients

Top-line data from the Phase I portion of a Phase I/IIa trial showed that CPCB-RPE1 from Regenerative Patch Technologies Inc. (Glendale, Calif.) was successfully implanted into an eye

Read the full 280 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE